Content about Cushing's syndrome

December 17, 2012

The Food and Drug Administration has approved a new drug to treat a rare but serious endocrine disorder.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a new drug to treat a rare but serious endocrine disorder.

Swiss drug maker Novartis announced the approval of Signifor (pasireotide), an injectable drug for treating Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative. Novartis said Signifor was the first drug to be approved in the United States that addresses the disease's underlying mechanism.

November 8, 2012

A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

EAST HANOVER, N.J. — A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

February 23, 2012

The Food and Drug Administration has approved a drug for a rare disorder that previously had no approved medical therapies, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for a rare disorder that previously had no approved medical therapies, the agency said.

The FDA announced the approval of Menlo Park, Calif.-based Corcept Therapeutics' Korlym (mifepristone) for endogenous Cushing's syndrome, a disorder that results from overproduction of cortisol, a steroid hormone that increases blood-sugar levels.

September 21, 2010

Swiss drug maker Novartis said its investigational drug is the first to show promise in...

EAST HANOVER, N.J. Swiss drug maker Novartis said its investigational drug is the first to show promise in a late-stage clinical trial for Cushing’s disease, a potentially fatal hormonal disorder.